Rocket Pharmaceuticals

Inotek, Rocket announce merger agreement

Wednesday, September 13, 2017

Inotek Pharmaceuticals has entered into a definitive merger agreement with Rocket Pharmaceuticals, a U.S.-based gene therapy company. Subject to shareholder approval, the combined company will retain the name Rocket Pharmaceuticals and will be headquartered in New York City. The combined company will focus on developing and advancing its pipeline of gene therapies based on lentiviral virus (LVV) and adeno-associated virus (AAV) gene therapy platforms, with a focus on treating devastating rare diseases.

[Read More]